JP2022533398A5 - - Google Patents
Info
- Publication number
- JP2022533398A5 JP2022533398A5 JP2021568865A JP2021568865A JP2022533398A5 JP 2022533398 A5 JP2022533398 A5 JP 2022533398A5 JP 2021568865 A JP2021568865 A JP 2021568865A JP 2021568865 A JP2021568865 A JP 2021568865A JP 2022533398 A5 JP2022533398 A5 JP 2022533398A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850289P | 2019-05-20 | 2019-05-20 | |
| US62/850,289 | 2019-05-20 | ||
| PCT/US2020/033816 WO2020236940A1 (en) | 2019-05-20 | 2020-05-20 | Kras g12c inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533398A JP2022533398A (ja) | 2022-07-22 |
| JP2022533398A5 true JP2022533398A5 (enExample) | 2023-05-29 |
| JP7502337B2 JP7502337B2 (ja) | 2024-06-18 |
Family
ID=73458223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568865A Active JP7502337B2 (ja) | 2019-05-20 | 2020-05-20 | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220227738A1 (enExample) |
| EP (1) | EP3972978A4 (enExample) |
| JP (1) | JP7502337B2 (enExample) |
| KR (1) | KR20220038289A (enExample) |
| CN (1) | CN114096544B (enExample) |
| AU (1) | AU2020279253A1 (enExample) |
| BR (1) | BR112021023359A2 (enExample) |
| CA (1) | CA3141604A1 (enExample) |
| IL (1) | IL288200A (enExample) |
| MX (1) | MX2021014177A (enExample) |
| SG (1) | SG11202112790SA (enExample) |
| WO (1) | WO2020236940A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| CN114630832A (zh) * | 2019-11-15 | 2022-06-14 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021139748A1 (en) * | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| WO2022040469A1 (en) * | 2020-08-19 | 2022-02-24 | The Trustees Of The Stevens Institute Of Technology | Spiro compounds as kras inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN114685502A (zh) | 2020-12-25 | 2022-07-01 | 由理生物医药（上海）有限公司 | 作为kras-g12c抑制剂的螺环类化合物 |
| CN114805311B (zh) * | 2021-01-21 | 2024-10-29 | 苏州亚盛药业有限公司 | 螺环茚 |
| WO2022240971A2 (en) * | 2021-05-11 | 2022-11-17 | 1200 Pharma Llc | Kras g12d inhibitors and uses thereof |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| CA3237274A1 (en) * | 2021-11-09 | 2023-05-19 | 1200 Pharma Llc | Select kras g12c inhibitors and uses thereof |
| WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023099608A1 (en) * | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CA3243798A1 (en) * | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025237091A1 (zh) * | 2024-05-17 | 2025-11-20 | 中山优理生物医药有限公司 | 螺环类化合物的制备方法及其中间体 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20100298289A1 (en) * | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2898765T3 (es) * | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
| CN110869357A (zh) * | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EA201992780A1 (ru) * | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| TW201942116A (zh) * | 2018-02-09 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌劑之四氫喹唑啉衍生物 |
| US11096939B2 (en) * | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MX2020012204A (es) * | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
| AU2019320945C1 (en) * | 2018-08-16 | 2021-09-30 | F. Hoffmann-La Roche Ag | Fused ring compounds |
| WO2021139748A1 (en) * | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| WO2022040469A1 (en) * | 2020-08-19 | 2022-02-24 | The Trustees Of The Stevens Institute Of Technology | Spiro compounds as kras inhibitors |
-
2020
- 2020-05-20 JP JP2021568865A patent/JP7502337B2/ja active Active
- 2020-05-20 MX MX2021014177A patent/MX2021014177A/es unknown
- 2020-05-20 EP EP20810811.8A patent/EP3972978A4/en active Pending
- 2020-05-20 US US17/612,972 patent/US20220227738A1/en active Pending
- 2020-05-20 AU AU2020279253A patent/AU2020279253A1/en not_active Abandoned
- 2020-05-20 SG SG11202112790SA patent/SG11202112790SA/en unknown
- 2020-05-20 BR BR112021023359A patent/BR112021023359A2/pt unknown
- 2020-05-20 WO PCT/US2020/033816 patent/WO2020236940A1/en not_active Ceased
- 2020-05-20 KR KR1020217041514A patent/KR20220038289A/ko not_active Ceased
- 2020-05-20 CN CN202080052231.0A patent/CN114096544B/zh active Active
- 2020-05-20 CA CA3141604A patent/CA3141604A1/en active Pending
-
2021
- 2021-11-17 IL IL288200A patent/IL288200A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533398A5 (enExample) | ||
| RU2495044C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2022545633A5 (enExample) | ||
| JP2017508789A5 (enExample) | ||
| JP2018511647A5 (enExample) | ||
| JP2020533347A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2003520235A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2019522055A5 (enExample) | ||
| JP2018507238A5 (enExample) | ||
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| CN115175905A (zh) | Zeste增强子同源物2抑制剂及其用途 | |
| RU2011133128A (ru) | Противоопухолевые соединения дигидропиран-2-она | |
| JP2013542267A5 (enExample) | ||
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2023553428A5 (enExample) | ||
| JP2023101521A5 (enExample) | ||
| RU2314292C2 (ru) | Производные азетидина в качестве антагонистов ccr-3 рецептора | |
| RU2007116987A (ru) | Новые соединения | |
| JP2023512206A5 (enExample) | ||
| JP2023512227A5 (enExample) |